Joanne Quan, M.D.
Joanne Quan, MD joined Mirum in 2024 as chief medical officer with responsibility for clinical development, clinical operations, and safety. Joanne has nearly three decades of experience developing novel therapeutics, including those for rare diseases.
Prior to Mirum, she served as chief medical officer at Nuvig Therapeutics. From 2018-2021, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc., and subsequently, UCB),. Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Genentech, and PathoGenesis.
Joanne received a BA in molecular biology at the University of California, Berkeley and an MD at Stanford University School of Medicine. She completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at the University of Washington.